TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07281079: A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

Sponsor: Neuren Pharmaceuticals Limited · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 160 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,111,504

Rescue Site Savings

+$2,074,336

Unlock Full NCT07281079 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07281079 Rescue Dossier →